Lupus Anticoagulant at Dr. Essa Lab

Lupus Anticoagulant at Dr. Essa Lab

The Lupus Anticoagulant test is a highly specialized panel of coagulation assays designed to detect the presence of antiphospholipid autoantibodies in the blood. Despite its confusing and paradoxical name, lupus anticoagulant is not an anticoagulant in the clinical sense; rather, it is a prothrombotic agent in vivo. While it prolongs clotting times during in vitro laboratory testing by interfering with phospholipid-dependent coagulation pathways, inside the human body, it significantly increases the risk of inappropriate blood clot formation (thrombosis) in both arteries and veins. This diagnostic evaluation is of paramount clinical importance, serving as a cornerstone for diagnosing Antiphospholipid Syndrome (APS), an autoimmune disorder characterized by recurrent vascular thrombosis and pregnancy-related complications.

At Dr. Essa Lab, the Lupus Anticoagulant panel is performed using state-of-the-art automated coagulation analyzers that utilize advanced optical and mechanical clot detection technologies. The test does not evaluate a single anatomical organ but rather assesses the physiological integrity of the entire vascular system and the complex biochemical cascade of blood coagulation. By measuring how long it takes for a patient’s plasma to clot in the presence of specific reagents, our consultant pathologists can pinpoint the presence of these interfering autoantibodies. The diagnostic value of this test is immense, providing clinicians with the critical evidence needed to guide long-term anticoagulation therapy, investigate unexplained miscarriages, and manage systemic autoimmune diseases like Systemic Lupus Erythematosus (SLE).

The primary benefit of undergoing this investigation at Dr. Essa Lab is our commitment to clinical precision. Coagulation testing is highly sensitive to pre-analytical variables, and our laboratory adheres to strict international guidelines to ensure that blood samples are collected, processed, and analyzed with the highest level of accuracy. Common clinical indications for this test include unexplained deep vein thrombosis (DVT), pulmonary embolism (PE), premature stroke, transient ischemic attacks (TIAs), and recurrent early pregnancy losses. By delivering reliable, reproducible results, Dr. Essa Lab helps healthcare providers make life-saving clinical decisions.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is vital to prevent pre-analytical errors and avoid false-positive or false-negative results. Patients must adhere to the following guidelines prior to sample collection:

• Disclose Medication History: You must inform your physician and the laboratory staff of all medications you are currently taking, especially blood thinners or anticoagulants such as Warfarin (Coumadin), Heparin, Low Molecular Weight Heparin (LMWH), or Direct Oral Anticoagulants (DOACs) like Rivaroxaban, Apixaban, and Dabigatran. These medications directly interfere with clotting assays and can cause false-positive lupus anticoagulant results.
• Timing of the Test: If you are on oral anticoagulant therapy, the test should ideally be performed when you have been off the medication for a period specified by your physician (often 1 to 2 weeks for Warfarin, or 48 hours for DOACs), or when the therapeutic effect is at its trough, under strict medical supervision.
• Fasting Requirements: While strict fasting is not universally mandatory, a light, non-fatty meal is highly recommended before the test. High levels of lipids (fats) in the blood (lipemia) can interfere with the optical detection systems used in automated coagulation analyzers.
• Hydration: Drink plenty of water before the procedure to ensure you are well-hydrated, which makes venipuncture easier and safer.
• Avoid Testing During Acute Thrombotic Events: Testing should ideally not be performed during an active clotting event or while the patient is receiving active heparin therapy, as the acute phase reactants and therapeutic drugs will compromise the validity of the test.

During the Procedure

The Lupus Anticoagulant test is a standard venipuncture procedure performed by our highly trained phlebotomists at Dr. Essa Lab. The process is quick, safe, and designed to minimize patient discomfort:

• Patient Positioning: You will be asked to sit comfortably in a phlebotomy chair or lie down. You should extend your arm, exposing the antecubital fossa (the inner elbow area).
• Sanitization and Tourniquet Application: The phlebotomist will apply a tourniquet around your upper arm to make the veins more visible and palpable. The puncture site will be thoroughly cleansed with an antiseptic solution (usually 70% isopropyl alcohol) and allowed to air dry.
• Sample Collection: A sterile, single-use needle will be inserted into the selected vein. Blood will be drawn into a light blue-top tube containing 3.2% buffered sodium citrate as an anticoagulant. The ratio of blood to anticoagulant (9:1) is extremely critical; therefore, the tube must be filled completely to the designated mark.
• Post-Puncture Care: Once the required volume of blood is collected, the needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze to prevent hematoma formation. A small adhesive bandage will be applied.
• Double Centrifugation (Processing): To ensure the highest accuracy, Dr. Essa Lab employs a specialized double-centrifugation protocol. This process removes virtually all platelets from the plasma sample (achieving platelet-poor plasma with a platelet count of less than 10,000/µL). This step is critical because platelets contain phospholipids that can neutralize lupus anticoagulants in vitro, leading to false-negative results during storage or freezing.
• Duration and Experience: The entire blood collection process takes less than five minutes. You may feel a brief, mild pinch as the needle enters the vein, but the procedure is virtually painless.

When is a Lupus Anticoagulant Performed?

Unexplained Venous or Arterial Thrombosis

Physicians request a Lupus Anticoagulant test when a patient presents with an unexplained blood clot in a vein or artery, particularly at a young age (under 50 years) or in an unusual anatomical location (such as the portal, hepatic, or cerebral veins). Symptoms of deep vein thrombosis include unilateral leg swelling, warmth, redness, and pain, while a pulmonary embolism may present with sudden shortness of breath, chest pain, and rapid heart rate. Identifying the presence of lupus anticoagulant helps determine if the thrombotic event was provoked by an underlying autoimmune hypercoagulable state, which requires long-term or lifelong anticoagulation therapy rather than a standard short-term course.

Recurrent Pregnancy Loss and Obstetric Complications

The test is strongly indicated for women who have experienced recurrent, unexplained pregnancy losses. According to international clinical criteria, this includes three or more consecutive spontaneous abortions before the 10th week of gestation, one or more unexplained fetal deaths at or beyond the 10th week of gestation, or one or more premature births before the 34th week of gestation due to severe preeclampsia, eclampsia, or placental insufficiency. Lupus anticoagulant antibodies can cause thrombosis in the placental blood vessels, leading to placental infarction and fetal growth restriction. Detecting these antibodies allows obstetricians to implement preventative therapies, such as low-dose aspirin and low molecular weight heparin, to improve pregnancy outcomes.

Evaluation of an Unexplained Prolonged aPTT

Often, a prolonged Activated Partial Thromboplastin Time (aPTT) is discovered incidentally during routine pre-operative screening or general health checkups in patients with no history of bleeding or clotting. When an aPTT is unexpectedly prolonged, clinical pathologists perform a mixing study, combining the patient’s plasma with normal pooled plasma. If the prolonged clotting time fails to correct, it indicates the presence of an inhibitor rather than a coagulation factor deficiency. A Lupus Anticoagulant test is then performed to confirm whether this inhibitor is a phospholipid-dependent antibody, helping to rule out bleeding disorders and confirm a prothrombotic risk.

Investigation of Systemic Lupus Erythematosus (SLE) and Autoimmune Disorders

Patients diagnosed with Systemic Lupus Erythematosus (SLE) or other systemic autoimmune conditions (such as rheumatoid arthritis, Sjögren’s syndrome, or systemic sclerosis) are frequently screened for lupus anticoagulant. Approximately 10% to 30% of patients with SLE possess lupus anticoagulant antibodies. While not all patients with these antibodies will develop blood clots, their presence represents a major risk factor. Regular screening and monitoring allow rheumatologists to stratify risk, counsel patients on avoiding other thrombotic risk factors (such as smoking or estrogen-containing oral contraceptives), and initiate prophylactic measures during high-risk periods like surgery or prolonged immobilization.

Diagnosis and Classification of Antiphospholipid Syndrome (APS)

To establish a definitive diagnosis of Antiphospholipid Syndrome (APS), clinical criteria require the presence of at least one clinical feature (vascular thrombosis or pregnancy morbidity) and at least one laboratory criteria met on two or more occasions at least 12 weeks apart. The Lupus Anticoagulant test is one of the three primary laboratory assays used for this purpose, alongside anti-cardiolipin and anti-beta-2-glycoprotein I antibody tests. Because lupus anticoagulant has the strongest association with clinical thrombosis among the three markers, its detection is crucial for accurate disease classification, risk profiling, and formulation of long-term therapeutic strategies.

What Does a Lupus Anticoagulant Detect?

The Lupus Anticoagulant panel is a multi-step testing algorithm that detects and confirms the presence of phospholipid-dependent autoantibodies. The testing process at Dr. Essa Lab evaluates several parameters to provide a comprehensive diagnostic picture:

• Prolonged Screening Clotting Time: Detects an initial delay in clotting during screening tests, such as the Dilute Russell’s Viper Venom Time (dRVVT) or the lupus anticoagulant-sensitive aPTT (aPTT-LA).
• Presence of a Coagulation Inhibitor: Confirmed when the patient’s plasma is mixed 1:1 with normal pooled plasma (mixing study) and the clotting time remains prolonged, demonstrating that the abnormality is due to an inhibitor rather than a clotting factor deficiency.
• Phospholipid Dependence of the Inhibitor: Confirmed when the addition of excess phospholipids to the test system shortens or normalizes the clotting time, proving that the antibody specifically targets phospholipids.
• Dilute Russell’s Viper Venom Time (dRVVT) Screen: Measures the time to clot activation via the extrinsic pathway using a low concentration of phospholipids and Russell’s viper venom, which directly activates Factor X.
• dRVVT Confirm Ratio: Measures clotting time in the presence of high phospholipid concentrations to neutralize the lupus anticoagulant, yielding a normalized ratio.
• Silica Clotting Time (SCT) Screen: An alternative screening test utilizing colloidal silica as an activator to initiate the intrinsic coagulation pathway.
• Silica Clotting Time Confirm: Uses excess phospholipids to confirm the phospholipid-dependent nature of the SCT prolongation.
• Hexagonal Phase Phospholipid Neutralization: A highly sensitive confirmatory test that utilizes hexagonal phase phosphatidylethanolamine to neutralize lupus anticoagulant antibodies.
• Distinction from Factor-Specific Inhibitors: Differentiates lupus anticoagulants from specific, dangerous coagulation factor inhibitors (such as Factor VIII inhibitors) that present with bleeding risks.
• False-Positives from Unfractionated Heparin: Detects the presence of therapeutic heparin in the sample, which can be neutralized using heparinase in the laboratory to ensure accurate interpretation.
• Interference from Low Molecular Weight Heparin (LMWH): Identifies potential false-positives caused by therapeutic levels of LMWH.
• Interference from Direct Oral Anticoagulants (DOACs): Identifies falsely elevated dRVVT ratios caused by medications like Rivaroxaban or Apixaban.
• Transient Lupus Anticoagulant: Detects temporary antibodies that may arise due to recent viral or bacterial infections, which typically resolve within 12 weeks.
• Persistent Lupus Anticoagulant: Confirms the persistent presence of the autoantibody when positive results are obtained on two separate tests performed at least 12 weeks apart.
• Primary Antiphospholipid Syndrome (APS): Detects the antibody in patients with no underlying systemic autoimmune disease.
• Secondary Antiphospholipid Syndrome (APS): Detects the antibody in association with systemic lupus erythematosus (SLE) or other connective tissue disorders.
• Triple Positivity Status: Identifies patients who are positive for Lupus Anticoagulant, anti-cardiolipin, and anti-beta-2-glycoprotein I, indicating the highest risk category for thrombosis and pregnancy loss.
• Double Positivity Status: Identifies patients positive for Lupus Anticoagulant and one other antiphospholipid antibody.
• Isolated Lupus Anticoagulant Positivity: Identifies patients who test positive only for lupus anticoagulant, which still carries a high clinical significance.
• Pre-analytical Platelet Contamination: Identifies potential false-negative results caused by inadequate centrifugation, where residual platelets release phospholipids during freeze-thaw cycles.
• Normal Coagulation Status: Confirms the absence of lupus anticoagulant antibodies, suggesting that other etiologies should be investigated for thrombotic or obstetric events.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that waiting for diagnostic results can be an anxious time for patients and their families. Because the Lupus Anticoagulant panel is a highly complex, multi-step assay requiring screening, mixing, and confirmatory testing, it demands meticulous laboratory execution. Typically, the turnaround time for a Lupus Anticoagulant test at Dr. Essa Lab is 24 to 48 hours from the time of sample collection. This timeline ensures that our consultant hematologists can carefully review the multi-stage testing ratios, perform necessary mixing studies, and provide a comprehensive, medically accurate interpretation.

Dr. Essa Lab offers seamless and convenient access to your diagnostic reports. Once your report is finalized and verified by our consultant pathologists, you will receive an automated SMS notification on your registered mobile number. You can easily view, download, and print your report directly from the official Dr. Essa Lab website or via our dedicated mobile application by entering your Lab ID and password. Additionally, physical copies of your reports can be collected from any of our conveniently located diagnostic centers across Karachi and other major cities in Pakistan. Our digital archiving system also ensures that your past medical reports are securely stored for future reference and comparative analysis.

Lupus Anticoagulant Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
dRVVT Screen Ratio	< 1.20 (Normal clotting time)	≥ 1.20 (Prolonged clotting time, suggesting the presence of an inhibitor)
dRVVT Confirm Ratio	Normalizes with excess phospholipids	Remains prolonged if a non-phospholipid-dependent inhibitor or factor deficiency is present
dRVVT Normalized Ratio	< 1.20 (Negative for Lupus Anticoagulant)	≥ 1.20 (Positive for Lupus Anticoagulant, indicating phospholipid dependence)
Silica Clotting Time (SCT) Ratio	< 1.16 (Normal)	≥ 1.16 (Prolonged, indicating potential lupus anticoagulant presence)
aPTT-LA (Lupus-sensitive aPTT)	Within normal reference range (seconds)	Significantly prolonged, suggesting an inhibitor or factor deficiency
1:1 Mixing Study (aPTT or dRVVT)	Correction of clotting time to normal range	Failure to correct clotting time (confirms the presence of a circulating inhibitor)
Hexagonal Phase Phospholipid Neutralization	Negative (No significant correction)	Positive (Significant shortening of clotting time, confirming lupus anticoagulant)
Thrombin Time (TT) / Reptilase Time	Within normal reference range	Prolonged TT with normal Reptilase Time indicates heparin contamination in the sample

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Lupus Anticoagulant?

• Experienced Healthcare Professionals: Our laboratory is directed and supervised by highly qualified consultant pathologists and hematologists with extensive experience in diagnosing complex coagulation disorders.
• Advanced Diagnostic Technology: Dr. Essa Lab utilizes fully automated, state-of-the-art coagulation analyzers that deliver highly precise, reproducible, and standardized results.
• Strict Quality Control: We adhere to rigorous internal quality control protocols and participate in international external quality assurance programs to maintain the highest standards of diagnostic accuracy.
• Specialized Processing Protocols: Our laboratory strictly follows double-centrifugation guidelines to prepare platelet-poor plasma, eliminating pre-analytical errors that cause false-negative results.
• Comprehensive Testing Panels: We offer complete antiphospholipid antibody profiling, including anti-cardiolipin and anti-beta-2-glycoprotein I assays, allowing for comprehensive clinical evaluation under one roof.
• Convenient Online Report Access: Patients can access their diagnostic reports securely from anywhere via our user-friendly website and mobile application.
• Extensive Network: With numerous collection centers across Karachi and Pakistan, patients can easily access our professional phlebotomy services close to home.
• Patient-Focused Care: We provide a comfortable, hygienic, and professional environment, ensuring a seamless and stress-free diagnostic experience for every patient.